Cargando…

Gene Dosage Analysis in a Clinical Environment: Gene-Targeted Microarrays as the Platform-of-Choice

The role of gene deletion and duplication in the aetiology of disease has become increasingly evident over the last decade. In addition to the classical deletion/duplication disorders diagnosed using molecular techniques, such as Duchenne Muscular Dystrophy and Charcot-Marie-Tooth Neuropathy Type 1A...

Descripción completa

Detalles Bibliográficos
Autores principales: Marquis-Nicholson, Renate, Prosser, Debra, Love, Jennifer M., Love, Donald R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5003480/
https://www.ncbi.nlm.nih.gov/pubmed/27605180
http://dx.doi.org/10.3390/microarrays2020051
_version_ 1782450655523241984
author Marquis-Nicholson, Renate
Prosser, Debra
Love, Jennifer M.
Love, Donald R.
author_facet Marquis-Nicholson, Renate
Prosser, Debra
Love, Jennifer M.
Love, Donald R.
author_sort Marquis-Nicholson, Renate
collection PubMed
description The role of gene deletion and duplication in the aetiology of disease has become increasingly evident over the last decade. In addition to the classical deletion/duplication disorders diagnosed using molecular techniques, such as Duchenne Muscular Dystrophy and Charcot-Marie-Tooth Neuropathy Type 1A, the significance of partial or whole gene deletions in the pathogenesis of a large number single-gene disorders is becoming more apparent. A variety of dosage analysis methods are available to the diagnostic laboratory but the widespread application of many of these techniques is limited by the expense of the kits/reagents and restrictive targeting to a particular gene or portion of a gene. These limitations are particularly important in the context of a small diagnostic laboratory with modest sample throughput. We have developed a gene-targeted, custom-designed comparative genomic hybridisation (CGH) array that allows twelve clinical samples to be interrogated simultaneously for exonic deletions/duplications within any gene (or panel of genes) on the array. We report here on the use of the array in the analysis of a series of clinical samples processed by our laboratory over a twelve-month period. The array has proven itself to be robust, flexible and highly suited to the diagnostic environment.
format Online
Article
Text
id pubmed-5003480
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-50034802016-09-06 Gene Dosage Analysis in a Clinical Environment: Gene-Targeted Microarrays as the Platform-of-Choice Marquis-Nicholson, Renate Prosser, Debra Love, Jennifer M. Love, Donald R. Microarrays (Basel) Article The role of gene deletion and duplication in the aetiology of disease has become increasingly evident over the last decade. In addition to the classical deletion/duplication disorders diagnosed using molecular techniques, such as Duchenne Muscular Dystrophy and Charcot-Marie-Tooth Neuropathy Type 1A, the significance of partial or whole gene deletions in the pathogenesis of a large number single-gene disorders is becoming more apparent. A variety of dosage analysis methods are available to the diagnostic laboratory but the widespread application of many of these techniques is limited by the expense of the kits/reagents and restrictive targeting to a particular gene or portion of a gene. These limitations are particularly important in the context of a small diagnostic laboratory with modest sample throughput. We have developed a gene-targeted, custom-designed comparative genomic hybridisation (CGH) array that allows twelve clinical samples to be interrogated simultaneously for exonic deletions/duplications within any gene (or panel of genes) on the array. We report here on the use of the array in the analysis of a series of clinical samples processed by our laboratory over a twelve-month period. The array has proven itself to be robust, flexible and highly suited to the diagnostic environment. MDPI 2013-03-27 /pmc/articles/PMC5003480/ /pubmed/27605180 http://dx.doi.org/10.3390/microarrays2020051 Text en © 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Article
Marquis-Nicholson, Renate
Prosser, Debra
Love, Jennifer M.
Love, Donald R.
Gene Dosage Analysis in a Clinical Environment: Gene-Targeted Microarrays as the Platform-of-Choice
title Gene Dosage Analysis in a Clinical Environment: Gene-Targeted Microarrays as the Platform-of-Choice
title_full Gene Dosage Analysis in a Clinical Environment: Gene-Targeted Microarrays as the Platform-of-Choice
title_fullStr Gene Dosage Analysis in a Clinical Environment: Gene-Targeted Microarrays as the Platform-of-Choice
title_full_unstemmed Gene Dosage Analysis in a Clinical Environment: Gene-Targeted Microarrays as the Platform-of-Choice
title_short Gene Dosage Analysis in a Clinical Environment: Gene-Targeted Microarrays as the Platform-of-Choice
title_sort gene dosage analysis in a clinical environment: gene-targeted microarrays as the platform-of-choice
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5003480/
https://www.ncbi.nlm.nih.gov/pubmed/27605180
http://dx.doi.org/10.3390/microarrays2020051
work_keys_str_mv AT marquisnicholsonrenate genedosageanalysisinaclinicalenvironmentgenetargetedmicroarraysastheplatformofchoice
AT prosserdebra genedosageanalysisinaclinicalenvironmentgenetargetedmicroarraysastheplatformofchoice
AT lovejenniferm genedosageanalysisinaclinicalenvironmentgenetargetedmicroarraysastheplatformofchoice
AT lovedonaldr genedosageanalysisinaclinicalenvironmentgenetargetedmicroarraysastheplatformofchoice